Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F 652

Next Previous
Drug Profile

F 652

Alternative Names: F-652; IL-22 IgG2 Fusion Protein; IL-22 IgG2-Fc; P-652; Recombinant Human Interleukin-22 IgG2-Fc; rhIL-22 dimer

Latest Information Update: 17 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Generon (Shanghai) Corporation
  • Developer Evive Biotech
  • Class Anti-inflammatories; Antivirals; Hepatoprotectants; Immunoglobulin Fc fragments; Interleukins; Recombinant fusion proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis; COVID 2019 infections; Graft-versus-host disease
  • No development reported Pancreatitis

Most Recent Events

  • 11 Jul 2025 Indiana University in collaboration with National Institute on Alcohol Abuse and Alcoholism plans a phase II trial for Alcoholic hepatitis and Alcoholism in the USA in August 2025 (NCT07060638)
  • 02 Oct 2023 Evive Biotech withdraws a phase II trial prior to enrolment for COVID-2019 pneumonia (IV), due to compound development plan changed (NCT05205668)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Pancreatitis in China (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top